- In April 2025, The U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for adult and pediatric patients aged 12 and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer
- In February 2025, the phase 3 CheckMate 274 trial reported that adjuvant nivolumab showed a statistically significant and clinically meaningful disease-free survival benefit versus placebo in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery
- In January 2025, Bristol Myers Squibb presented results from the CheckMate -8HW analysis, evaluating nivolumab plus ipilimumab compared to nivolumab monotherapy, showing a 38% reduction in the risk of disease progression or death when treated with the combination therapy
- September 2024, A study published in The New England Journal of Medicine reported that patients with advanced melanoma treated with nivolumab plus ipilimumab experienced continued, ongoing survival benefits over a 10-year period
